RESUMO
Using six Enterococcus faecalis and five Enterococcus faecium strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Ery(s)) and -intermediate (Ery(i)) enterococci (ABT 50% protective doses [PD(50)s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Ery(r)) strains for which ABT MICs were low, ABT showed much greater activity (PD(50), 6.3 to 32.5 mg/kg) than ERY (PD(50), >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.
Assuntos
Eritromicina/uso terapêutico , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Cetolídeos , Peritonite/tratamento farmacológico , Animais , Contagem de Colônia Microbiana , Enterococcus faecium/efeitos dos fármacos , Eritromicina/análogos & derivados , Eritromicina/farmacologia , Infecções por Bactérias Gram-Positivas/microbiologia , Dose Letal Mediana , Camundongos , Camundongos Endogâmicos ICR , Testes de Sensibilidade Microbiana , Peritonite/microbiologiaRESUMO
A novel glycylcycline agent, tigecycline (GAR-936), was evaluated in vivo in the mouse model of peritonitis against three Enterococcus faecalis and four Enterococcus faecium isolates with different susceptibilities to vancomycin and tetracyclines, all of which were inhibited by